MedPath

Vsiqq

Brand Name: Vsiqq

Generic Name: Brolucizumab

Active
Registration Number

BR-1397

Dosage Form

Solution for Injection (Intravitreal)

Issuance Date

April 1, 2022

Expiry Date

April 1, 2027

Product Information

Philippine FDA product specifications and classification details

Product Specifications

Dosage Strength120 mg/mL (27.6 mg/0.23 mL)
PackagingSingle use 0.23 mL in 2 mL Ph. Eur. Type I colourless glass vial with grey rubber stopper and an aluminum seal with violet flip-off cap +1 1/2" 18G filter needle in a soft blister

Classification

C
Classification
Prescription Drug (RX)
P
Pharmacologic
Antineovascularization Agent
A
Application
Monitored Release (MR)
Philippine FDA Classification

Active Ingredients (1)

Complete list of active ingredients in this pharmaceutical product.

BrolucizumabActive
Monograph: Brolucizumab

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.

MedPath - Medical Intelligence Platform